Meiragtx (MGTX) traded down -5.73 % during a 24 hours period ending at 11:15 PM Central Europe on Monday 26th. One Meiragtx stock can currently be bought for about USD 9.18 on popular exchanges. Current supply of Meiragtx stocks is 96 mn. Meiragtx has a current market capitalization of USD 884.6 mn and approximately USD 5.5 mn worth of Meiragtx was traded on exchanges in the last 24 hours. Since last month end, Meiragtx has traded -16.65 % down. Simple moving average of last 200 days is at USD 10.26. The highest price of past 52 weeks was recorded at USD 15.35 on 07/07/2026. 52 weeks low was at USD 6.62 on 03/05/2026.

Here is how related stocks have performed in the past 24 hours:

  • Horizon / (HBNC) traded up 1.9 % and now trades at USD 20.79. Horizon / has a market capitalisation of USD 1 bn. Current price/earnings ratio for Horizon / is 9.76.

  • Mercantile Bank (MBWM) traded up 1.11 % and now trades at USD 61.15. Mercantile Bank has a market capitalisation of USD 1.1 bn. Mercantile Bank has a current price to earnings ratio of 10.92.

  • Power Internationa (PSIX) traded down -3.26 % and now trades at USD 45.63. Current market capitalisation for Power Internationa is USD 1.1 bn. Power Internationa has a current price to earnings ratio of 16.04.

  • Cnb /Pa (CCNE) traded up 0.31 % and now trades at USD 35.55. Current market capitalisation for Cnb /Pa is USD 1 bn. Cnb /Pa has a current price to earnings ratio of 10.52.

  • Arrivent Biopharma (AVBP) traded up 9.38 % and now trades at USD 15.36. Current market capitalisation for Arrivent Biopharma is USD 1 bn. ArriVent BioPharma announced early Phase 1 results for its CDH17‑targeting antibody‑drug conjugate, ARR‑217, at the ESMO Congress. The study, conducted in heavily pre‑treated gastrointestinal cancer patients, showed encouraging tumor response and disease‑control rates, with a majority of patients maintaining treatment through the data‑cutoff. Safety data indicated a manageable profile, with most adverse events being low‑grade and no serious events of the highest severity reported. The company is now advancing ARR‑217 into a Phase 1b dose‑optimization phase at higher doses, with further data expected in 2027. This progress marks a significant milestone for ArriVent’s antibody‑drug conjugate pipeline and highlights the potential of CDH17 as a therapeutic target in gastrointestinal malignancies.

About Meiragtx

MeiraGTx Holdings plc is a clinical stage gene therapy company operating in the health care sector, specializing in biotechnology. The company offers a diverse pipeline of preclinical and research programs, as well as provides gene therapy manufacturing and transformative gene regulation technology. MeiraGTx Holdings serves patients in the United States. You can find more information about the company on their website, www.meiragtx.com , and they are listed on the Nasdaq stock exchange.